Emergent BioSolutions announced that it completed the sale of a drug product facility in Maryland to an affiliate of Bora Pharmaceuticals. The Gaithersburg, Maryland-based Narcan maker announced the sale of the facility to Bora in June. Bora paid approximately $30 million at closing for the facility, located in Baltimore-Camden. The site made up part of…

Emergent BioSolutions this week announced it entered into a definitive agreement to sell its Baltimore-Camden drug product facility. The Gaithersburg, Maryland-based company will sell the facility to an affiliate of Bora Pharmaceuticals for approximately $30 million. Emergent’s Camden site is part of the company’s Contract Development and Manufacturing Organization (CDMO) and has clinical and commercial…

Bora Pharmaceuticals announced that its board approved the acquisition of Upsher-Smith Laboratories for up to $210 million. Minnesota-based Upsher-Smith features a diversified portfolio of 48 generic products. It has manufacturing facilities in Plymouth and Maple Grove, Minnesota. Taipei, Taiwan-based Bora called the company a reliable partner with solid manufacturing capabilities, a robust distribution network and…